pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
554
stories
Jun 4, 26
ADC biotech Ona Therapeutics secures $86.6M in Series B raise
endpoints
Jun 4, 26
A Spanish biotech banks $87M to make differentiated ADCs
biopharma dive
Jun 2, 26
ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
biopharma dive
Jun 1, 26
RallyBio tries again for reverse merger, this time with Avenzo
biopharma dive
May 31, 26
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
stat
May 31, 26
Akeso, Summit drug extends survival in closely watched lung cancer trial
biopharma dive
May 30, 26
STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
stat
May 29, 26
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
biopharma dive
May 29, 26
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
endpoints
May 29, 26
Allogene CEO to step down; Agios drug fails key test
biopharma dive
May 29, 26
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
stat
May 29, 26
Pfizer, Innovent strike $10B cancer drug deal
biopharma dive
May 29, 26
Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs
endpoints
May 28, 26
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
endpoints
May 19, 26
A migraine drugmaker heads to the public markets through reverse merger
biopharma dive
May 18, 26
With no approved vaccine for Ebola outbreak, experts weigh testing a long shot
stat
May 18, 26
Merck ADC, licensed from China, hits mark in first big global trial
biopharma dive
May 18, 26
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
biopharma dive
May 18, 26
Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule
endpoints
May 15, 26
FDA Approves T-DXd for Early-Stage HER2+ Breast Cancer
onclive
May 15, 26
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
biopharma dive
May 14, 26
AstraZeneca follows Merck with Phase 3 win in bladder cancer
endpoints
May 14, 26
STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
stat
May 14, 26
Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss
onclive
May 13, 26
Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice
onclive
May 13, 26
FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
onclive
May 13, 26
FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma
onclive
May 13, 26
Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
onclive
May 13, 26
Future Directions in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer
onclive
← prev
page 15 of 19
next →
